
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN

Cash Flow Statement
Cash Flow Statement
Lincoln Pharmaceuticals Ltd
Mar-2021 | Sep-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | Sep-2024 | ||
---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | |||||||||
Net Income |
837
|
893
|
959
|
934
|
1 005
|
1 098
|
1 222
|
1 242
|
|
Depreciation & Amortization |
76
|
77
|
81
|
87
|
92
|
98
|
106
|
119
|
|
Other Non-Cash Items |
(25)
|
(54)
|
(59)
|
(46)
|
(86)
|
(179)
|
(278)
|
(312)
|
|
Cash Taxes Paid |
195
|
218
|
237
|
249
|
296
|
290
|
262
|
273
|
|
Cash Interest Paid |
12
|
11
|
10
|
10
|
14
|
15
|
13
|
14
|
|
Change in Working Capital |
(196)
|
(241)
|
(220)
|
(647)
|
(618)
|
(219)
|
(419)
|
(402)
|
|
Cash from Operating Activities |
693
N/A
|
675
-3%
|
761
+13%
|
328
-57%
|
393
+20%
|
799
+103%
|
632
-21%
|
647
+2%
|
|
Investing Cash Flow | |||||||||
Capital Expenditures |
(88)
|
(264)
|
(455)
|
(351)
|
(143)
|
(137)
|
(396)
|
(394)
|
|
Other Items |
(555)
|
(457)
|
(326)
|
(84)
|
(224)
|
(388)
|
(177)
|
(263)
|
|
Cash from Investing Activities |
(642)
N/A
|
(721)
-12%
|
(781)
-8%
|
(435)
+44%
|
(366)
+16%
|
(525)
-43%
|
(573)
-9%
|
(657)
-15%
|
|
Financing Cash Flow | |||||||||
Net Issuance of Debt |
(46)
|
(75)
|
15
|
9
|
(1)
|
(110)
|
(9)
|
4
|
|
Cash Paid for Dividends |
0
|
0
|
(30)
|
0
|
(30)
|
(33)
|
(30)
|
(31)
|
|
Other |
(12)
|
(11)
|
(10)
|
(10)
|
(14)
|
(15)
|
(13)
|
(14)
|
|
Cash from Financing Activities |
(58)
N/A
|
(87)
-51%
|
(26)
+70%
|
(31)
-21%
|
(45)
-45%
|
(158)
-251%
|
(52)
+67%
|
(41)
+21%
|
|
Change in Cash | |||||||||
Net Change in Cash |
(7)
N/A
|
(132)
-1 761%
|
(45)
+66%
|
(138)
-207%
|
(19)
+86%
|
116
N/A
|
7
-94%
|
(51)
N/A
|
|
Free Cash Flow | |||||||||
Free Cash Flow |
605
N/A
|
411
-32%
|
306
-26%
|
(23)
N/A
|
250
N/A
|
662
+165%
|
236
-64%
|
253
+7%
|